Please login to the form below

Not currently logged in
Email:
Password:

NeuroTherm appoints Gregory Cash as president and CEO

Joins pain management device manufacturers from HeartSine

Gregory Cash has been appointed president and CEO of US-based pain management device company NeuroTherm.

He joins from HeartSine Technologies, where he also served as president and CEO.

“This is a key appointment at an important time for NeuroTherm, and we are certain that Greg's leadership combined with his strategic vision  and experience make him the right person to lead the company through the next phase of rapid growth and development,” said Eric Bacon, chair of the board of directors at NeuroTherm.

Prior to his time at HeartSine, Cash served in numerous senior management roles of progressive responsibility in the US, Asia and Europe.

“While there are many challenges facing the medical device industry as a whole, NeuroTherm is poised for strong growth and will continue to make a positive difference in patients' lives,” said Cash.

24th September 2012

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Real Science Communications

Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics